BEAM
GILD icon

Baker Ellis Asset Management’s Gilead Sciences GILD Stock Holding History

Baker Ellis Asset Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,450
Closed -$203K – 209
2023
Q1 		$203K Hold
2,450
– – 0.04% 194
2022
Q4 		$210K Buy
+2,450
New +$194K 0.04% 188

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baker Ellis Asset Management's GILD Position: Q2 2023 in Review

Baker Ellis Asset Management sold out of Gilead Sciences (GILD) in Q2 2023, closing a stake of 2,450 shares — an estimated $203K sold.

Baker Ellis Asset Management first reported a position in GILD in Q4 2022 and held it in 2 quarters. The position peaked at $210K in Q4 2022. 1,701 funds tracked by Wall St. Rank hold GILD as of Q2 2023.

  • Baker Ellis Asset Management reported no remaining Gilead Sciences position as of Q2 2023 after selling out during the quarter.
  • Baker Ellis Asset Management sold 2,450 Gilead Sciences shares in Q2 2023, an estimated $203K.
  • Baker Ellis Asset Management first reported a position in Gilead Sciences in Q4 2022 and held it in 2 quarters.
  • Baker Ellis Asset Management's Gilead Sciences position peaked at $210K in Q4 2022.
  • 1,701 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2023.

Based on Baker Ellis Asset Management's 13F filing for Q2 2023, filed 9 Aug 2023.